The earnings call presented strong financial metrics and promising advancements in MannKind's product pipeline, particularly with significant growth in Tyvaso DPI and Afrezza revenues. However, there were challenges noted in V-Go revenue and manufacturing timing, as well as trial enrollment difficulties in the U.S. for Nintedanib DPI. Despite these challenges, the overall outlook remains positive with strategic plans and financial resources in place to support future growth.

Company Guidance -

Q3 2025

During the MannKind Corporation Second Quarter 2025 Financial Results Conference Call, CEO Michael Castagna provided guidance focusing on shareholder value and strategic growth. The company highlighted its financial strength with Q2 revenues at $77 million, a 6% increase over 2024, and a robust balance sheet featuring $201 million in cash. MannKind announced a significant financial partnership with Blackstone, ensuring access to $500 million in nondilutive capital to fuel growth. Key operational highlights included record Tyvaso DPI sales, impressive Afrezza revenue of $18.3 million reflecting a 13% year-over-year growth, and promising advancements in their pipeline, notably the inhaled clofazimine and Nintedanib DPI programs. The company plans to expand its sales force, particularly in anticipation of a pediatric Afrezza launch, and aims to increase market coverage to approximately 50% by 2026.

Record Revenue in Tyvaso DPI Sales

Achieved record revenue from Tyvaso DPI sales, with Q2 royalties contributing $31 million, an increase of 22% over the same quarter last year.

Strong Financial Position

MannKind has a strong balance sheet with $201 million in cash and access to $500 million from Blackstone for nondilutive capital to accelerate growth and innovation.

Afrezza Growth and Expansion

Afrezza net revenues for Q2 were $18 million, a 13% increase over the prior year, with year-over-year growth of 22% on new prescriptions.

Advancement in Nintedanib DPI

Nintedanib DPI for IPF is moving forward into Phase II with a trial named INFLO, expected to launch by year-end 2025.

Inhaled Clofazimine Developments

Enrollment in the ICoN-1 trial for inhaled Clofazimine is progressing well with 90 patients enrolled, aiming for 100 evaluable patients by 2026.

MannKind (MNKD) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

MNKD Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 11, 2025	2025 (Q3)	0.02 / -	0.04	―	―	―
Aug 06, 2025	2025 (Q2)	0.05 / 0.00	-0.01	―	―
May 08, 2025	2025 (Q1)	0.04 / 0.04	0.04	0.00% (0.00)	―
Feb 26, 2025	2024 (Q4)	0.04 / 0.03	0	―
Nov 07, 2024	2024 (Q3)	0.03 / 0.04	0.01	300.00% (+0.03)	―
Aug 07, 2024	2024 (Q2)	<0.01 / -0.01	-0.02	50.00% (+0.01)
May 08, 2024	2024 (Q1)	0.03 / 0.04	-0.04	200.00% (+0.08)
Feb 27, 2024	2023 (Q4)	<0.01 / 0.00	-0.07	―
Nov 07, 2023	2023 (Q3)	-0.02 / 0.01	-0.06	116.67% (+0.07)	―
Aug 07, 2023	2023 (Q2)	-0.04 / -0.02	-0.11	81.82% (+0.09)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

MNKD Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 06, 2025	$3.99	$3.46	-13.28%
May 08, 2025	$4.85	$4.63	-4.54%
Feb 26, 2025	$5.47	$5.23	-4.39%
Nov 07, 2024	$7.39	$7.34	-0.68%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Mannkind Corp. (MNKD) report earnings?

Mannkind Corp. (MNKD) is schdueled to report earning on Nov 11, 2025, TBA (Confirmed).

What is Mannkind Corp. (MNKD) earnings time?

Mannkind Corp. (MNKD) earnings time is at Nov 11, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is MNKD EPS forecast?

MNKD EPS forecast for the fiscal quarter 2025 (Q3) is 0.02.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing